Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
企業コードAMIX
会社名Autonomix Medical Inc
上場日Jan 29, 2024
最高経営責任者「CEO」Hauser (Bradley)
従業員数8
証券種類Ordinary Share
決算期末Jan 29
本社所在地21 Waterway Ave, Suite 300
都市THE WOODLANDS
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号77380
電話番号18322777816
ウェブサイトhttps://autonomix.com/
企業コードAMIX
上場日Jan 29, 2024
最高経営責任者「CEO」Hauser (Bradley)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし